Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.56 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.56 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.56 |
| ▸ | TLR2 | O60603 | 8/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | PRKCG | P05129 | 1/20 | 0.46 |
| ▸ | PRKCB | P05771 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
| ▸ | PRKCH | P24723 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.46 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.46 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.45 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7564861 | 1.00 | DNM1 (0.74) | DNM1HTTLPAR1LPAR3LPAR2 | |
| SCHEMBL19839744 | 1.00 | DNM1 (0.74) | DNM1HTTLPAR1LPAR3LPAR2 | |
| SCHEMBL7558267 | 1.00 | DNM1 (0.74) | DNM1HTTLPAR1LPAR3LPAR2 | |
| SCHEMBL7560842 | 1.00 | DNM1 (0.74) | DNM1HTTLPAR1LPAR3LPAR2 | |
| SCHEMBL22589994 | 1.00 | DNM1 (0.74) | DNM1HTTLPAR1LPAR3LPAR2 | |
| SCHEMBL24470437 | 1.00 | DNM1 (0.74) | DNM1HTTLPAR1LPAR3LPAR2 | |
| SCHEMBL7560937 | 1.00 | DNM1 (0.74) | DNM1HTTLPAR1LPAR3LPAR2 | |
| SCHEMBL19839669 | 1.00 | DNM1 (0.74) | DNM1HTTLPAR1LPAR3LPAR2 | |
| SCHEMBL7564999 | 1.00 | DNM1 (0.74) | DNM1HTTLPAR1LPAR3LPAR2 | |
| SCHEMBL7557137 | 1.00 | DNM1 (0.74) | DNM1HTTLPAR1LPAR3LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002072068-A2 | LIPIDS, LIPID COMPOSITIONS, LIPOSOMES, AND LIPOPLEXES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-09-19 | — | — | WO | claimed |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4655402-A1 | NUCLEIC ACID VACCINES FOR VARICELLA-ZOSTER VIRUS (VZV) | Providence Therapeutics Holdings Inc. (CA) | 2025-12-03 | — | — | EP | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2025-03-06 | — | — | US | disclosed |
| US-12215068-B2 | Constrained lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4452928-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-3041938-A1 | CIRCULAR POLYNUCLEOTIDES | Moderna Therapeutics, Inc. (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20160194625-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNATX, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160194368-A1 | CIRCULAR POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160038612-A1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | ARES CAPITAL CORPORATION, AS AGENT | 2016-02-11 | — | — | US | disclosed |
| WO-2016014846-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF INTRABODIES | MODERNA THERAPEUTICS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| WO-2015105926-A1 | POLYNUCLEOTIDES FOR THE IN VIVO PRODUCTION OF ANTIBODIES | MODERNA THERAPEUTICS, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015038892-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | MODERNA THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | WO | disclosed |
| WO-2015034925-A1 | CIRCULAR POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015034928-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2002072068-A2 | LIPIDS, LIPID COMPOSITIONS, LIPOSOMES, AND LIPOPLEXES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038612-A1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, ADAR | DNM1 1822/4885HTT 457/4885LPAR1 1644/4885 |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | DNM1 1315/4885HTT 2652/4885LPAR1 262/4885 |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | DNM1 4235/4885HTT 1246/4885LPAR1 114/4885 |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | SGMS1, SGMS2, ABCB4 | DNM1 3554/4885HTT 4142/4885LPAR1 616/4885 |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | PLTP, LNPEP, PCTP | DNM1 625/4885HTT 2716/4885LPAR1 140/4885 |
| US-20160194368-A1 | CIRCULAR POLYNUCLEOTIDES | POLN, POLRMT, POLI | DNM1 1372/4885HTT 593/4885LPAR1 1429/4885 |
| US-12215068-B2 | Constrained lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | DNM1 1315/4885HTT 2652/4885LPAR1 262/4885 |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | DNM1 1472/4885HTT 3454/4885LPAR1 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.